A significant drop in stock price raises concerns for investors.
Helix BioPharma Corp. saw its stock price plunge by 19.31% yesterday, closing at CA$1.17. This sharp decline has caught the attention of investors who are watching the company's performance closely amid ongoing financial challenges.
Investor takeaway: The steep drop in Helix BioPharma's stock price highlights the volatility often associated with small-cap biotech firms, especially those that have yet to turn a profit.
Advertisement
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$84.02M
52W high
$5.40
52W low
$1.10
1W change
-21.43%
Beta
-0.27
Analyst Price Targets
Based on analyst covering HBP · as of Sep 17, 2026
Wall Street analysts forecast HBP stock price to rise 127.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+127.3% Upside
Current Price
C$1.10
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
99.0%
Annualized
90-Day Vol
67.9%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.92
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.04 | C$0.74 – C$1.46 |
| 60 trading days | C$0.98 | C$0.60 – C$1.58 |
| 90 trading days | C$0.92 | C$0.51 – C$1.66 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Stock fell 19.31% yesterday
Helix BioPharma's market cap now stands at CA$89.36 million, reflecting investor concerns about its financial viability.
Bull case
Investors may find potential in Helix BioPharma if the company can overcome its financial hurdles and successfully advance its development pipeline, which could lead to future gains.
Bear case
The recent drop signals deeper issues within the company, including ongoing financial losses and a lack of profitability, which could deter potential investors and lead to further declines.
Market Reaction
Advertisement
The 19.31% drop in Helix BioPharma's stock reflects broader concerns among investors about the company's financial health. With a market cap of CA$89.36 million, the stock's performance is closely monitored by those interested in small-cap biotech investments. The absence of recent positive news may have contributed to the sell-off, as investors look for stability and growth potential.
Financial Overview
Helix BioPharma has faced challenges with profitability, reporting a net loss of CA$5.2 million for the fiscal year ending July 31, 2025. This ongoing financial struggle raises questions about the company's ability to sustain operations and attract new investment. For more details on Helix BioPharma's financial performance, check out their latest fiscal results.
Future Outlook
Investors will be eager to see how Helix BioPharma tackles its financial issues moving forward. The company's ability to stabilize operations and regain investor confidence will be crucial for any potential recovery in its stock price. For ongoing updates, visit the Helix BioPharma stock page.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
